Network meta-analysis of the prognosis of curative treatment strategies for recurrent hepatocellular carcinoma after hepatectomy

Figure 2 Pooled mean survival rates of disease-free and overall survival of the patients treated by repeated hepatectomy, radiofrequency ablation, transarterial chemoembolization, or liver transplantation in recurrent hepatocellular carcinoma from all studies. A and B: The results of transarterial chemoembolization (TACE) disclosed the inferiority to other treatment options in disease-free survival (DFS) (A) or overall survival (B). The data of DFS were recorded and pooled together from recurrent-free survival in one arm of repeated hepatectomy and radiofrequency ablation and two arms of liver transplantation (LT), progression-free survival in one arm of TACE, and tumor-free rate in one arm of LT. DFS: Disease-free survival; LT: Liver transplantation; OS: Overall survival; RH: Repeated hepatectomy; RFA: Radiofrequency ablation; TACE: Transarterial chemoembolization.